Monopar Therapeutics (MNPR) Institutional Ownership and Insiders Activity

Monopar Therapeutics (MNPR) is widely held by institutional investors, with 93 firms reporting positions valued at approximately $525.65M based on SEC Form 13F filings for the quarter ended June 30, 2026.

Janus Henderson Group Plc is the largest disclosed holder, reporting approximately $72.06M in MNPR holdings in its latest filing.